From: The personalized treatment of invasive candidiasis still has a long way to go
Variable | n = 63 |
---|---|
Male gender, n (%) | 45 (71.4) |
Age, median (IQR) | 48 (32,75) |
Types of candida | |
Candida albicans, n (%) | 39 (61.9) |
Candida glabrata, n (%) | 17 (26.9) |
Candida parapsilosis, n (%) | 7 (11.2) |
Lymphocyte, median (IQR), 10^9 count/L | 1.43 (0.72,1.94) |
Time of positive blood culture, median (IQR), hour | 21 (13,45) |
(1,3)-β-D-Glucan, median (IQR), pg/mL | 175 (102,427) |
De-escalation therapy, n (%) | 17 (31.7) |
Course of antifungal therapy, median (IQR), day | 9 (6,13) |
Long of ICU stay, median (IQR), day | 5 (3,8) |
Long of hospital stay, median (IQR), day | 10 (7,16) |
Mortality, n (%) | 0 (0) |
Recurrence rate, n (%) | 0 (0) |